Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 1/2022

Open Access 01-02-2022 | Pruritus | Guidelines

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

Authors: Hong You, Xiong Ma, Cumali Efe, Guiqiang Wang, Sook-Hyang Jeong, Kazumichi Abe, Weijia Duan, Sha Chen, Yuanyuan Kong, Dong Zhang, Lai Wei, Fu-Sheng Wang, Han-Chieh Lin, Jin Mo Yang, Tawesak Tanwandee, Rino A. Gani, Diana A. Payawal, Barjesh C. Sharma, Jinlin Hou, Osamu Yokosuka, A. Kadir Dokmeci, Darrell Crawford, Jia-Horng Kao, Teerha Piratvisuth, Dong Jin Suh, Laurentius A. Lesmana, Jose Sollano, George Lau, Shiv K. Sarin, Masao Omata, Atsushi Tanaka, Jidong Jia

Published in: Hepatology International | Issue 1/2022

Login to get access

Excerpt

Primary biliary cholangitis (PBC) is a chronic intrahepatic cholestatic disease with not fully elucidated pathogenesis. Immunological dysfunction triggered by environmental factors may render autoimmunity against the interlobular bile ducts in genetically predisposed hosts. PBC typically affects middle-aged women, commonly presents with fatigue and pruritus, or with an asymptomatic elevation of serum alkaline phosphatase (ALP)/glutamyl transpeptidase (GGT). The pathological features are progressive, non-suppurative, destructive intrahepatic cholangitis, leading to fibrosis and eventually cirrhosis. Antimitochondrial antibodies (AMAs), especially the M2 subtype (AMA-M2), are highly sensitive and specific for PBC in clinical settings. Currently, ursodeoxycholic acid (UDCA) is the treatment of choice for this disease. …
Literature
1.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926PubMedPubMedCentralCrossRef
2.
Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188PubMedCrossRef
3.
Lv T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;36:1423–1434PubMedCrossRef
4.
Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia–Pacific region: a systematic review and meta-analysis. Hepatol Int. 2019;13:788–799PubMedCrossRef
5.
Ngu JH, Gearry RB, Wright AJ, et al. Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. Hepatol Int. 2012;6:796–800PubMedCrossRef
6.
Sood S, Gow PJ, Christie JM, et al. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127:470–475PubMedCrossRef
7.
Sakugawa H, Nakasone H, Nakayoshi T, et al. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa Japan. Hepatol Res. 2003;26:330–336PubMedCrossRef
8.
Shibata M, Onozuka Y, Morizane T, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol. 2004;39:255–259PubMedCrossRef
9.
10.
Liu H, Liu Y, Wang L, et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol. 2010;10:100PubMedPubMedCentralCrossRef
11.
Kim KA, Ki M, Choi HY, et al. Population-based epidemiology of primary biliary cirrhosis in South Korea. Aliment Pharmacol Ther. 2016;43:154–162PubMedCrossRef
12.
Tanaka A, Mori M, Matsumoto K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49:881–889PubMedCrossRef
13.
Cheung KS, Seto WK, Fung J, et al. Epidemiology and natural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8:e116PubMedPubMedCentralCrossRef
14.
Amarapurkar DN, Patel ND. Spectrum of autoimmune liver diseases in western India. J Gastroenterol Hepatol. 2007;22:2112–2117PubMedCrossRef
15.
Lleo A, Leung PSC, Hirschfield GM, et al. The pathogenesis of primary biliary cholangitis: a comprehensive review. Semin Liver Dis. 2020;40:34–48PubMedCrossRef
16.
Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17:93–110PubMedCrossRef
17.
Wijarnpreecha K, Werlang M, Panjawatanan P, et al. Association between smoking and risk of primary biliary cholangitis: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2019;28:197–203PubMedCrossRef
18.
Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology. 2006;43:525–531PubMedCrossRef
19.
Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59:508–512PubMedCrossRef
20.
Corpechot C, Chrétien Y, Chazouillères O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53:162–169PubMedCrossRef
21.
Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018;67:534–541PubMedCrossRef
22.
23.
Carbone M, Lleo A, Sandford RN, et al. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol. 2014;44:945–954PubMedPubMedCentralCrossRef
24.
Wang C, Zheng X, Jiang P, et al. Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis. Hepatology. 2019;70:294–307PubMedCrossRef
25.
Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013;8:303–330PubMedCrossRef
26.
Hitomi Y, Ueno K, Kawai Y, et al. POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Sci Rep. 2019;9:102PubMedPubMedCentralCrossRef
27.
28.
Selmi C, Lleo A, Pasini S, et al. Innate immunity and primary biliary cirrhosis. Curr Mol Med. 2009;9:45–51PubMedCrossRef
29.
Kikuchi K, Lian ZX, Yang GX, et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005;128:304–312PubMedCrossRef
30.
Shimoda S, Harada K, Niiro H, et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology. 2010;51:567–575PubMedCrossRef
31.
Mao TK, Lian ZX, Selmi C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology. 2005;42:802–808PubMedCrossRef
32.
Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology. 2011;140:1120-1125.e1–12PubMedCrossRef
33.
Tsuda M, Ambrosini YM, Zhang W, et al. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology. 2011;54:1293–1302PubMedCrossRef
34.
Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 2006;43:729–737PubMedCrossRef
35.
Zhang H, Lian M, Zhang J, et al. A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. Hepatology. 2018;67:232–246PubMedCrossRef
36.
Li SX, Lv TT, Zhang CP, et al. Alteration of liver-infiltrated and peripheral blood double-negative T cells in primary biliary cholangitis. Liver Int. 2019;39:1755–1767PubMedCrossRef
37.
Jiang X, Lian M, Li Y, et al. The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7. J Autoimmun. 2018;90:64–75PubMedCrossRef
38.
Kyriakou DS, Alexandrakis MG, Zachou K, et al. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2003;39:679–685PubMedCrossRef
39.
Zachou K, Rigopoulou EI, Tsikrikoni A, et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun. 2005;25:283–288PubMedCrossRef
40.
Tsikrikoni A, Kyriakou DS, Rigopoulou EI, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2005;42:393–399PubMedCrossRef
41.
42.
Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394–419PubMed
43.
EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–172CrossRef
44.
Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67:1568–1594PubMedCrossRef
45.
Chen S, Duan W, Li M, et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: a single center follow-up study from China. J Gastroenterol Hepatol. 2018;34:1236–1241PubMedCrossRef
46.
Lin CY, Cheng YT, Chang ML, et al. The extrahepatic events of Asian patients with primary biliary cholangitis: a 30-year cohort study. Sci Rep. 2019;9:7577PubMedPubMedCentralCrossRef
47.
Murillo PCF, Goet JC, Lammers WJ, et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology. 2018;67:1920–1930CrossRef
48.
Kubota J, Ikeda F, Terada R, et al. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol. 2009;44:1000–1006PubMedCrossRef
49.
Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865–870PubMedPubMedCentralCrossRef
50.
51.
Carbone M, Bufton S, Monaco A, et al. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol. 2013;59:490–494PubMedCrossRef
52.
Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79-83PubMedCrossRef
53.
Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54:1622–1629PubMedPubMedCentralCrossRef
54.
Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2010;7:313–319PubMedCrossRef
55.
56.
Yagi M, Tanaka A, Abe M, et al. Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. Sci Rep. 2018;8:12542PubMedPubMedCentralCrossRef
57.
Hegade VS, Bolier R, Oude ERP, et al. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Front Gastroenterol. 2016;7:158–166CrossRef
58.
59.
Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:192–197PubMedCrossRef
60.
Efe C, Torgutalp M, Henriksson I, et al. Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol. 2021;36:936–942PubMedCrossRef
61.
Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;26:831–838PubMedCrossRef
62.
Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol. 1995;10:438–445PubMedCrossRef
63.
Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795–1800PubMedPubMedCentralCrossRef
64.
Fan J, Wang Q, Sun L. Association between primary biliary cholangitis and osteoporosis: meta-analysis. Clin Rheumatol. 2017;36:2565–2571PubMedCrossRef
65.
Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis. 2003;7:901–910PubMedCrossRef
66.
Colina F, Pinedo F, Solís JA, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology. 1992;102:1319–1324PubMedCrossRef
67.
Rong G, Wang H, Bowlus CL, et al. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:132–141PubMedCrossRef
68.
Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 2013;57:1942–1949PubMedCrossRef
69.
Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel). 2021;13:1023CrossRef
70.
Granito A, Muratori P, Quarneti C, et al. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12:65–74PubMedCrossRef
71.
Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Rev Mol Diagn. 2016;16:1001–1010PubMedCrossRef
72.
Vergani D. Towards the serological diagnosis of primary biliary cirrhosis. Liver Int. 2015;35:299–301PubMedCrossRef
73.
Dalekos GN, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases. Arch Immunol Ther Exp (Warsz). 2019;67:197–211CrossRef
74.
Gabeta S, Norman GL, Liaskos C, et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol. 2007;27:378–87.PubMedCrossRef
75.
Liu H, Norman GL, Shums Z, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436–42.PubMedCrossRef
76.
Muratori L, Muratori P, Granito A, et al. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Dig Liver Dis. 2005;37:108–112PubMedCrossRef
77.
Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46:1436–1442PubMedCrossRef
78.
Zhang Q, Liu Z, Wu S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Gastroenterol Res Pract. 2019;2019:8959103PubMedPubMedCentralCrossRef
79.
Granito A, Muratori P, Muratori L, et al. Antinuclear antibodies giving the “multiple nuclear dots” or the “rim-like/membranous” patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24:1575–1583PubMedCrossRef
80.
Norman GL, Yang CY, Ostendorff HP, et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642–651PubMedCrossRef
81.
Janka C, Selmi C, Gershwin ME, et al. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology. 2005;41:609–616PubMedCrossRef
82.
Granito A, Yang WH, Muratori L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:125–131PubMedCrossRef
83.
Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert Rev Clin Immunol. 2014;10:1667–1678PubMedCrossRef
84.
Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–127PubMedCrossRef
85.
Haliloglu N, Erden A, Erden I. Primary biliary cirrhosis: evaluation with T2-weighted MR imaging and MR cholangiopancreatography. Eur J Radiol. 2009;69:523–527PubMedCrossRef
86.
Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198–208PubMedCrossRef
87.
Friedrich-Rust M, Müller C, Winckler A, et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J Clin Gastroenterol. 2010;44:58–65PubMedCrossRef
88.
Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–112PubMedCrossRef
89.
Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J. 1983;59(Suppl 4):106–115PubMed
90.
Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology. 1999;29:1007–1012PubMedCrossRef
91.
Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;122:652–658PubMedCrossRef
92.
Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int. 2010;60:167–174PubMedCrossRef
93.
Harada K, Hsu M, Ikeda H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol. 2013;47:174–181PubMedCrossRef
94.
Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol. 2013;44:1107–1117PubMedCrossRef
95.
Papamichalis PA, Zachou K, Papamichali RA, et al. Promyelocytic leukemia antigen expression: a histological marker for primary biliary cholangitis diagnosis. J Transl Int Med. 2021;9:43–51PubMedPubMedCentralCrossRef
96.
Corpechot C, Gaouar F, Chrétien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 2012;56:218–224PubMedCrossRef
97.
Híndi M, Levy C, Couto CA, et al. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2013;47:e28-32PubMedCrossRef
98.
Minuk GY, Iliant V, Zhou N, et al. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver Int. 2018;38:1110–1116PubMedCrossRef
99.
Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis). Zhonghua Gan Zang Bing Za Zhi 2016;24:5–13.
100.
Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 (Suppl S1):71–90.
101.
Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol. 1999;30:830–835PubMedCrossRef
102.
Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016;95:e5391CrossRef
103.
Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551PubMed
104.
Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799–1807PubMedCrossRef
105.
Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101:1529–1538PubMedCrossRef
106.
Poupon RE, Lindor KD, Parés A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol. 2003;39:12–16PubMedCrossRef
107.
Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644–647PubMedCrossRef
108.
Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303PubMedCrossRef
109.
Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357–365PubMedCrossRef
110.
Leoni MC, Amelung L, Lieveld FI, et al. Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver disease. Clin Res Hepatol Gastroenterol. 2019;43:37–44PubMedCrossRef
111.
Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–877PubMedCrossRef
112.
Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144:560-569.e7 (quiz e13–14)PubMedCrossRef
113.
Gatselis NK, Goet JC, Zachou K, et al. Factors associated with progression and outcomes of early stage primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18:684-692.e6PubMedCrossRef
114.
Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology. 2013;58:264–272PubMedCrossRef
115.
Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130:715–720PubMedCrossRef
116.
Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115–121PubMedCrossRef
117.
Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281–1287PubMedCrossRef
118.
Azemoto N, Abe M, Murata Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol. 2009;44:630–634PubMedCrossRef
119.
Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–2194PubMedCrossRef
120.
Momah N, Silveira MG, Jorgensen R, et al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012;32:790–795PubMedCrossRef
121.
Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–1367PubMedCrossRef
122.
Chen S, Duan W, You H, et al. A brief review on prognostic models of primary biliary cholangitis. Hepatol Int. 2017;11:412–418PubMedCrossRef
123.
Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804-1812.e4PubMedCrossRef
124.
Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930–950PubMedCrossRef
125.
Efe C, Taşçilar K, Henriksson I, et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis. Am J Gastroenterol. 2019;114:1101–1108PubMedCrossRef
126.
Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338-1349.e5 (quiz e15)PubMedCrossRef
127.
Murillo PCF, Harms MH, Lindor KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115:1066–1074CrossRef
128.
Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;3:626–634PubMedPubMedCentralCrossRef
129.
Yagi M, Matsumoto K, Komori A, et al. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver Int. 2020;40:1926–1933PubMedCrossRef
130.
Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-761.e8PubMedCrossRef
131.
Kowdley KV, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67:1890–1902PubMedCrossRef
132.
Nevens F, Andreone P, Mazzella G, et al. A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643PubMedCrossRef
133.
Trauner M, Nevens F, Shiffman ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4:445–453PubMedCrossRef
134.
Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis. 2012;13:219–224PubMedCrossRef
135.
Ohira H, Sato Y, Ueno T, et al. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol. 2002;97:2147–2149PubMedCrossRef
136.
Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015;9:2757–2766PubMedPubMedCentral
137.
Duan W, Ou X, Wang X, et al. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Rev Esp Enferm Dig. 2018;110:557–563PubMedCrossRef
138.
Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther. 2015;9:5407–19.PubMedPubMedCentral
139.
Reig A, Sesé P, Parés A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol. 2018;113:49–55PubMedCrossRef
140.
Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171–2181PubMedCrossRef
141.
Honda A, Tanaka A, Kaneko T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology. 2019;70:2035–2046PubMedCrossRef
142.
de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized placebo-controlled Trial. Gastroenterology. 2021;160:734-743.e6PubMedCrossRef
143.
Bolier R, de Vries ES, Parés A, et al. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. 2017;18:230PubMedPubMedCentralCrossRef
144.
Rautiainen H, Kärkkäinen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005;41:747–752PubMedCrossRef
145.
Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918–925PubMedCrossRef
146.
Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74:321–329PubMedCrossRef
147.
Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196–202PubMedCrossRef
148.
Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399–407PubMedCrossRef
149.
Yu H, Zhao T, Liu S, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife. 2019;8:48431CrossRef
150.
Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323–332PubMedCrossRef
151.
Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102:1528–1536PubMedCrossRef
152.
Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26:943–948PubMedCrossRef
153.
Bachs L, Parés A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574–576PubMedCrossRef
154.
Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436–439PubMedPubMedCentralCrossRef
155.
Markowitz JS, DeVane CL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J Clin Psychopharmacol. 2000;20:109–110PubMedCrossRef
156.
Yagi M, Tanaka A, Namisaki T, et al. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. 2018;53:1151–1158PubMedCrossRef
157.
Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114–1123PubMedCrossRef
158.
Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459–467PubMedCrossRef
159.
EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019;70:172–193.
160.
Guo GY, Shi YQ, Wang L, et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment Pharmacol Ther. 2015;42:221–230PubMedCrossRef
161.
Agmon-Levin N, Kopilov R, Selmi C, et al. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol Res. 2015;61:141–146PubMedCrossRef
162.
Wang Z, Peng C, Wang P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol. 2020;55:1333–1340PubMedCrossRef
163.
Guañabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology. 2010;138:2348–2356PubMedCrossRef
164.
Rudic JS, Giljaca V, Krstic MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev 2011;CD009144.
165.
Guañabens N, Monegal A, Cerdá D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58:2070–2078PubMedCrossRef
166.
Rudic JS, Poropat G, Krstic MN et al. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev 2011;CD009146.
167.
Arase Y, Tsuruya K, Hirose S, et al. Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases. Hepatology. 2019;71:757–759PubMedCrossRef
168.
Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;25:471–476PubMedCrossRef
169.
Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol. 2014;13:316–326PubMedCrossRef
170.
Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S, et al. Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114:446–452PubMedCrossRef
171.
Cavazza A, Caballería L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 2009;50:1162–1168PubMedCrossRef
172.
Trivedi PJ, Lammers WJ, van Buuren HR, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65:321–329PubMedCrossRef
173.
Harada K, Nakanuma Y. Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis. Hepatol Res. 2014;44:133–140PubMedCrossRef
174.
Natarajan Y, Tansel A, Patel P, et al. Incidence of hepatocellular carcinoma in primary biliary cholangitis: a systematic review and meta-analysis. Dig Dis Sci. 2020;66:2439–2451PubMedCrossRef
175.
Aguilar MT, Carey EJ. Current status of liver transplantation for primary biliary cholangitis. Clin Liver Dis. 2018;22:613–624PubMedCrossRef
176.
Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–1165PubMedCrossRef
177.
Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675–688PubMedCrossRef
178.
Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014;60:210–223PubMedCrossRef
179.
Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755–760PubMedCrossRef
180.
Montano-Loza AJ, Hansen BE, Corpechot C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology. 2019;156:96-107.e1PubMedCrossRef
181.
Khettry U, Anand N, Faul PN, et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 2003;9:87–96PubMedCrossRef
182.
Silveira MG, Talwalkar JA, Lindor KD, et al. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010;10:720–726PubMedCrossRef
183.
Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol. 2015;63:1449–1458PubMedCrossRef
184.
Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–385PubMedCrossRef
185.
Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015). J Dig Dis 2017;18:247–264.
186.
Dyson JK, De Martin E, Dalekos GN, et al. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther. 2019;49:528–536PubMedCrossRef
187.
Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301PubMedCrossRef
188.
Yang F, Wang Q, Bian Z, et al. Autoimmune hepatitis: east meets west. J Gastroenterol Hepatol. 2015;30:1230–1236PubMedCrossRef
189.
Terziroli BB, Mieli-Vergani G, Vergani D, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun. 2019;105:CrossRef
190.
Wang Q, Selmi C, Zhou X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun. 2013;41:140–145PubMedCrossRef
191.
Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104:1420–1425PubMedCrossRef
192.
Efe C, Purnak T, Ozaslan E, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2010;105:226 (author reply 226–227)PubMedCrossRef
193.
Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8:530–534PubMedCrossRef
194.
Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176PubMedCrossRef
195.
Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938PubMedCrossRef
196.
Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol. 2016;50:114–123PubMedCrossRef
197.
Tanaka A, Harada K, Ebinuma H, et al. Primary biliary cirrhosis—autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res. 2011;41:877–886PubMed
198.
Zhang H, Li S, Yang J, et al. A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations. Prz Gastroenterol. 2015;10:148–155PubMedPubMedCentral
199.
Ozaslan E, Efe C, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014;12:863–869PubMedCrossRef
200.
Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:323–331 (viii–ix)PubMedCrossRef
201.
Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090–1095PubMedCrossRef
202.
Jin Q, Moritoki Y, Lleo A, et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology. 2012;55:1495–1506PubMedCrossRef
203.
Juliusson G, Imam M, Björnsson ES, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745–752PubMedCrossRef
204.
Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348:1399–1402PubMedCrossRef
205.
Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017;65:152–163PubMedCrossRef
206.
Gulamhusein AF, Juran BD, Atkinson EJ, et al. Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up. Liver Int. 2016;36:1378–1382PubMedPubMedCentralCrossRef
207.
Mattalia A, Quaranta S, Leung PS, et al. Characterization of antimitochondrial antibodies in health adults. Hepatology. 1998;27:656–661PubMedCrossRef
208.
Ohba K, Omagari K, Kinoshita H, et al. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki Japan. J Clin Epidemiol. 2001;54:845–850PubMedCrossRef
209.
Chen BH, Wang QQ, Zhang W, et al. Screening of anti-mitochondrial antibody subtype M2 in residents at least 18 years of age in an urban district of Shanghai China. Eur Rev Med Pharmacol Sci. 2016;20:2052–2060PubMed
210.
Sun C, Xiao X, Yan L, et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker. J Autoimmun. 2019;99:33–38PubMedCrossRef
211.
Terziroli BB, Stirnimann G, Mertens J, et al. Primary biliary cholangitis with normal alkaline phosphatase: a neglected clinical entity challenging current guidelines. J Autoimmun. 2021;116:102578CrossRef
212.
Poupon R, Chrétien Y, Chazouillères O, et al. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol. 2005;42:418–419PubMedCrossRef
213.
Efe C, Kahramanoğlu-Aksoy E, Yilmaz B, et al. Pregnancy in women with primary biliary cirrhosis. Autoimmun Rev. 2014;13:931–935PubMedCrossRef
214.
Floreani A, Infantolino C, Franceschet I, et al. Pregnancy and primary biliary cirrhosis: a case–control study. Clin Rev Allergy Immunol. 2015;48:236–242PubMedCrossRef
215.
Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019;394:849–860PubMedPubMedCentralCrossRef
216.
Kong X, Kong Y, Zhang F, et al. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: a meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016;95:e4949CrossRef
217.
218.
Wellge BE, Sterneck M, Teufel A, et al. Pregnancy in primary sclerosing cholangitis. Gut. 2011;60:1117–1121PubMedCrossRef
219.
Rudi J, Schönig T, Stremmel W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy. Z Gastroenterol. 1996;34:188–191PubMed
220.
Vítek L, Zelenková M, Brůha R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Dig Liver Dis. 2010;42:911–912PubMedCrossRef
221.
222.
Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology. 1980;78:236–246PubMedCrossRef
223.
Locke GR, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology. 1996;23:52–56PubMedCrossRef
224.
Springer J, Cauch-Dudek K, O’Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol. 1999;94:47–53PubMedCrossRef
225.
Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044–1051PubMedCrossRef
226.
Cheung AC, Lammers WJ, Murillo PCF, et al. Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2019;17:2076-2084.e2PubMedCrossRef
227.
Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int. 2015;35:636–641PubMedCrossRef
228.
Jones DE, Al-Rifai A, Frith J, et al. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010;53:911–917PubMedCrossRef
229.
Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528–532PubMedPubMedCentralCrossRef
230.
Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135–1144PubMedCrossRef
231.
Huang C, Han W, Wang C, et al. Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: a meta-analysis. Dis Markers. 2019;2019:9121207PubMedPubMedCentralCrossRef
232.
Gatselis NK, Zachou K, Norman GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471–479PubMedCrossRef
233.
Roll J, Boyer JL, Barry D, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983;308:1–7PubMedCrossRef
234.
Vleggaar FP, van Buuren HR, Zondervan PE, et al. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut. 2001;49:276–281PubMedPubMedCentralCrossRef
235.
Murillo PCF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50:1127–1136CrossRef
Metadata
Title
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis
Authors
Hong You
Xiong Ma
Cumali Efe
Guiqiang Wang
Sook-Hyang Jeong
Kazumichi Abe
Weijia Duan
Sha Chen
Yuanyuan Kong
Dong Zhang
Lai Wei
Fu-Sheng Wang
Han-Chieh Lin
Jin Mo Yang
Tawesak Tanwandee
Rino A. Gani
Diana A. Payawal
Barjesh C. Sharma
Jinlin Hou
Osamu Yokosuka
A. Kadir Dokmeci
Darrell Crawford
Jia-Horng Kao
Teerha Piratvisuth
Dong Jin Suh
Laurentius A. Lesmana
Jose Sollano
George Lau
Shiv K. Sarin
Masao Omata
Atsushi Tanaka
Jidong Jia
Publication date
01-02-2022
Publisher
Springer India
Published in
Hepatology International / Issue 1/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10276-6

Other articles of this Issue 1/2022

Hepatology International 1/2022 Go to the issue

Original Article

Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke

Letter to the Editor

Response to “Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria”

Original Article

A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes

Original Article

Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study

Editorial

Non-alcoholic fatty liver disease in cerebrovascular disease: a bystander or a real risk factor?

Original Article

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits